Lisata Therapeutics — Caladrius Biosciences — Investor Presentation (April 2017)

6 slides from Lisata Therapeutics's investor presentation, Apr 27, 2017

Slide 1: Corporate Presentation April 2017
> BIOSCIENCES Corporate Presentation April 2017 | NASDAQ: CLBS
Slide 2: Forward-looking statements advisory
Forward-looking statements advisory 9 Litigation Reform Act of 1995. Forward-looking f : All statement: i financial result Thi ? the ious factors. rom those "Risk Factors" 10-K filed with the Securities and Exchange Commission ("SEC") on March 17, 201 r it EC, includi related to: (i) (i) he signific
Slide 3: Hitachi Chemical
HitachiChemical
Slide 4: Focused, funded and poised for growth
a caladrius BIOSCIENCES Focused, funded and poised for growth’ » Pure-play Cell Therapy » Phase 2 protocol in Critical Limb Ischemia therapeutics development company for CLBS12 ready to initiate in Japan - Positive results should qualify product for early conditional approval in Japan + Well-funded
Slide 5: Caladrius offers multiple potential near-term value creating milestones
Caladrius offers multiple potential near-term value creating milestones Expected Timeframe DSMB safety assessment on 1* patient cohort Initiation of enrollment of 2% patient cohort 50% of patients treated: starts clock to 6-mos. follow-up interim analysis Mic2017; CLBS03 70" patient enrolled: trigge
Slide 6: Investor Relations contact
¥ BIOSCIENCES NASDAQ: CLBS LHA Investor Relations Anne Marie Fields, Sd Vice President je: 212.838.3777 Ema [email protected] Web: www.caladrius.com